Antengene Corporation Limited announced that XPOVIO® (selinexor) in combination with bortezomib and dexamethasone (XVd) is now listed on the PBS for the treatment of adult patients with R/R MM who have received at least one prior therapy. MM accounts for about 10% of all blood malignancies and 1.6% of all cancers across Australia1. Around 2,400 people are newly diagnosed each year with MM, and around 20,000 patients are living with MM at a time.

Unfortunately, around 1,000 people will die from this form of blood cancer in any given year2 in Australia, and newly listed XVd offers an additional treatment option for these patients. In the Phase III BOSTON study, once-weekly XVd demonstrated a significantly greater overall response rate (ORR) compared with twice-weekly Vd, with over three in four patients responding to treatment, including patients with renal impairment as well as patients with both standard-risk and high-risk cytogenetics. The primary endpoint was progression-free survival (PFS) in the intention-to-treat (ITT) population.

The PFS was 13.93 months for once-weekly XVd vs 9.46 months for twice-weekly Vd (HR:0.70 [95%Cl, 0.53,0.93] p=0.0075). The ORRs were 76.4% for XVd vs 62.3% for Vd (OR:1.96 (1.3,3.1) p=0.0012). XVd demonstrated a PFS of 21 months in patients aged =65 years vs 9.5 months for patients on Vd.3 Xd is the only PBS-listed treatment clinically proven to work in daratumumab-refractory patients.

XVd was also associated with a PFS of over 10 months in lenalidomide-refractory patients4. XPOVIO®'s adverse event (AE) profile is predictable, reversible, transient, and manageable through dose adjustment and proactive support care. Professor Hang Quach, Haematologist, St Vincent's Hospital Melbournesaid, "I was privileged to be one of the investigators in the BOSTON study.

Selinexor is the first-in-class exportin-1 (XPO1) inhibitor that is effective in the treatment of MM.